GCM
PBYI icon

Graham Capital Management’s Puma Biotechnology PBYI Stock Holding History

Graham Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-52,708
Closed -$280K – 1512
2025
Q3 		$280K Buy
+52,708
New +$224K ﹤0.01% 894
2025
Q2 		– Sell
-12,752
Closed -$37.7K – 1537
2025
Q1 		$37.7K Buy
12,752
+2,020
+19% +$6.32K ﹤0.01% 1239
2024
Q4 		$32.7K Buy
+10,732
New +$31.2K ﹤0.01% 1195

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Graham Capital Management's PBYI Position: Q4 2025 in Review

Graham Capital Management sold out of Puma Biotechnology (PBYI) in Q4 2025, closing a stake of 52,708 shares — an estimated $280K sold.

Graham Capital Management first reported a position in PBYI in Q4 2024 and held it in 3 quarters. The position peaked at $280K in Q3 2025. 151 funds tracked by Wall St. Rank hold PBYI as of Q4 2025.

  • Graham Capital Management reported no remaining Puma Biotechnology position as of Q4 2025 after selling out during the quarter.
  • Graham Capital Management sold 52,708 Puma Biotechnology shares in Q4 2025, an estimated $280K.
  • Graham Capital Management first reported a position in Puma Biotechnology in Q4 2024 and held it in 3 quarters.
  • Graham Capital Management's Puma Biotechnology position peaked at $280K in Q3 2025.
  • 151 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2025.

Based on Graham Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.